

Table 1. Demographic and clinical characteristics patients with normal-tension glaucoma (NTG), high-tension glaucoma (HTG), and healthy controls.

Variable	NTG	HTG	Control	P-value
Number of Patients	99	69	50	
Age, mean ($\pm$ SD) (years)	72.3 ($\pm$ 10.1)	73.6 ($\pm$ 9.6)	68.4 ($\pm$ 10.1)	0.018
Sex, male/female (n)	63/36	37/32	29/21	0.42
Smoking, n (%)	5 (5.1%)	4 (5.8%)	4 (8.0%)	0.71
Alcohol consumption (n (% yes))	76 (76.8%)	51 (73.4%)	40 (80.0%)	0.74
Diabetes, n (%)	3 (3.0%)	10 (14.5%)	3 (6.0%)	0.019
On treatment for systemic Hypertension, n (%)	32 (32.3%)	28 (40.6%)	21 (42.0%)	0.40
On treatment for high cholesterol, n (%)	32 (32.3%)	29 (42.0%)	20 (40.0%)	0.39
Number of systemic pathologies, median (IQR)	1 (0 – 2)	2 (1 – 2)	1 (0 – 2)	0.20
Vasospasm, n (%)	31 (44.9%)	7 (10.1%)	3 (6.0%)	<0.001
Migraine, n (%)	16 (16.1%)	12 (17.4%)	4 (8.0%)	0.31
BMI, mean ($\pm$ SD)	24.2 ($\pm$ 3.7)	25.8 ($\pm$ 4.9)	28.0 ($\pm$ 5.5)	<0.001
Vitamin D, n (%)	18 (18.2%)	15 (21.7%)	12 (24.0%)	0.68
Thyroxine supplement, n (%)	6 (6.1%)	10 (14.5%)	1 (2.0%)	0.047
ACE Inhibitors, n (%)	8 (8.1%)	14 (20.3%)	11 (22.0%)	0.029
ARB, n (%)	7 (7.1%)	1 (1.4%)	5 (10.0%)	0.11
BB, n (%)	16 (16.2%)	11 (15.9%)	12 (24.0%)	0.44
CCB, n (%)	18 (18.2%)	5 (7.2%)	7 (14.0%)	0.13
Diuretic, n (%)	8 (8.1%)	10 (14.5%)	7 (14.0%)	0.36
PGA drops, n (%)	60 (60.6%)	51 (73.9%)	N/A	0.10*
CAI drops, n (%)	37 (37.4%)	24 (34.8%)	N/A	0.86*
BB drops, n (%)	31 (31.3%)	25 (36.2%)	N/A	0.62*
a2A drops, n (%)	2 (2.0%)	6 (8.7%)	N/A	0.07*

BMI: Body mass index; ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blockers; BB: Beta blockers; CCB: Calcium channel blockers; PGA: Prostaglandin analogues; CAI: Carbonic anhydrase inhibitors; a2A: alpha 2-agonists
IQR: interquartile range; *: analysis done in two groups

